Natural products as catalysts for innovation: a pharmaceutical industry perspective

Natural products are evolutionarily designed and chemically distinct from most synthetic library molecules. In addition to their role as drugs, they are successfully used as molecular probes to identify disease relevant targets. Novel natural products are still routinely discovered from traditional...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in chemical biology 2011-08, Vol.15 (4), p.497-504
Main Authors: Schmitt, Esther K, Moore, Charles M, Krastel, Philipp, Petersen, Frank
Format: Article
Language:English
Subjects:
Biodiversity
Biological Products - chemistry
Drug Discovery - methods
Drug Industry - methods
Epigenomics - methods
Genome
High-Throughput Screening Assays - methods
Humans
Molecular Probes - chemistry
Molecular Structure
Technology, Pharmaceutical - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c421t-69164231aa48dad34c0ba7c6e3381f5261a0995f84bea270b82031b65dae59463
cites cdi_FETCH-LOGICAL-c421t-69164231aa48dad34c0ba7c6e3381f5261a0995f84bea270b82031b65dae59463
container_end_page 504
container_issue 4
container_start_page 497
container_title Current opinion in chemical biology
container_volume 15
creator Schmitt, Esther K
Moore, Charles M
Krastel, Philipp
Petersen, Frank
description Natural products are evolutionarily designed and chemically distinct from most synthetic library molecules. In addition to their role as drugs, they are successfully used as molecular probes to identify disease relevant targets. Novel natural products are still routinely discovered from traditional sources through cultivation of microorganisms. Complementary approaches based on genome sequence information and subsequent annotation of biosynthetic pathways are emerging technologies. However, to be of practical use for drug discovery, these concepts must be advanced beyond their current state.
doi_str_mv 10.1016/j.cbpa.2011.05.018
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_892955080</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1367593111000871</els_id><sourcerecordid>892955080</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-69164231aa48dad34c0ba7c6e3381f5261a0995f84bea270b82031b65dae59463</originalsourceid><addsrcrecordid>eNp9kE1L7DAUhoMofv-Bu7h056r1JG0yqdzNRfwC0YW6DqfpKWbotDVJB-bfm2HUpaucwPO-nPMw9odDwYGry2VhmwkLAZwXIAvgeo8dc72oc6hA7Ke5VItc1iU_YichLAFACS0P2ZHgSlca4Ji9PGGcPfbZ5Md2tjFkGDKLEftNSJ9u9JkbhnGN0Y3DVYbZ9I5-hZbm6GyKuaGdQ_SbbCIfJrLRremMHXTYBzr_ek_Z2-3N6_V9_vh893D9_zG3leAxVzVXlSg5YqVbbMvKQoMLq6gsNe-kUByhrmWnq4ZQLKDRAkreKNkiybpS5Sm72PWm3T9mCtGsXLDU9zjQOAeja1FLCRoSKXak9WMInjozebdCvzEczNalWZqtS7N1aUCa5DKF_n7Vz82K2p_It7wE_NsBlI5cO_ImWEeDpdb5ZMK0o_ut_xOIaIXN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>892955080</pqid></control><display><type>article</type><title>Natural products as catalysts for innovation: a pharmaceutical industry perspective</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Schmitt, Esther K ; Moore, Charles M ; Krastel, Philipp ; Petersen, Frank</creator><creatorcontrib>Schmitt, Esther K ; Moore, Charles M ; Krastel, Philipp ; Petersen, Frank</creatorcontrib><description>Natural products are evolutionarily designed and chemically distinct from most synthetic library molecules. In addition to their role as drugs, they are successfully used as molecular probes to identify disease relevant targets. Novel natural products are still routinely discovered from traditional sources through cultivation of microorganisms. Complementary approaches based on genome sequence information and subsequent annotation of biosynthetic pathways are emerging technologies. However, to be of practical use for drug discovery, these concepts must be advanced beyond their current state.</description><identifier>ISSN: 1367-5931</identifier><identifier>EISSN: 1879-0402</identifier><identifier>DOI: 10.1016/j.cbpa.2011.05.018</identifier><identifier>PMID: 21684800</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Biodiversity ; Biological Products - chemistry ; Drug Discovery - methods ; Drug Industry - methods ; Epigenomics - methods ; Genome ; High-Throughput Screening Assays - methods ; Humans ; Molecular Probes - chemistry ; Molecular Structure ; Technology, Pharmaceutical - methods</subject><ispartof>Current opinion in chemical biology, 2011-08, Vol.15 (4), p.497-504</ispartof><rights>2011 Elsevier Ltd</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-69164231aa48dad34c0ba7c6e3381f5261a0995f84bea270b82031b65dae59463</citedby><cites>FETCH-LOGICAL-c421t-69164231aa48dad34c0ba7c6e3381f5261a0995f84bea270b82031b65dae59463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21684800$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schmitt, Esther K</creatorcontrib><creatorcontrib>Moore, Charles M</creatorcontrib><creatorcontrib>Krastel, Philipp</creatorcontrib><creatorcontrib>Petersen, Frank</creatorcontrib><title>Natural products as catalysts for innovation: a pharmaceutical industry perspective</title><title>Current opinion in chemical biology</title><addtitle>Curr Opin Chem Biol</addtitle><description>Natural products are evolutionarily designed and chemically distinct from most synthetic library molecules. In addition to their role as drugs, they are successfully used as molecular probes to identify disease relevant targets. Novel natural products are still routinely discovered from traditional sources through cultivation of microorganisms. Complementary approaches based on genome sequence information and subsequent annotation of biosynthetic pathways are emerging technologies. However, to be of practical use for drug discovery, these concepts must be advanced beyond their current state.</description><subject>Biodiversity</subject><subject>Biological Products - chemistry</subject><subject>Drug Discovery - methods</subject><subject>Drug Industry - methods</subject><subject>Epigenomics - methods</subject><subject>Genome</subject><subject>High-Throughput Screening Assays - methods</subject><subject>Humans</subject><subject>Molecular Probes - chemistry</subject><subject>Molecular Structure</subject><subject>Technology, Pharmaceutical - methods</subject><issn>1367-5931</issn><issn>1879-0402</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9kE1L7DAUhoMofv-Bu7h056r1JG0yqdzNRfwC0YW6DqfpKWbotDVJB-bfm2HUpaucwPO-nPMw9odDwYGry2VhmwkLAZwXIAvgeo8dc72oc6hA7Ke5VItc1iU_YichLAFACS0P2ZHgSlca4Ji9PGGcPfbZ5Md2tjFkGDKLEftNSJ9u9JkbhnGN0Y3DVYbZ9I5-hZbm6GyKuaGdQ_SbbCIfJrLRremMHXTYBzr_ek_Z2-3N6_V9_vh893D9_zG3leAxVzVXlSg5YqVbbMvKQoMLq6gsNe-kUByhrmWnq4ZQLKDRAkreKNkiybpS5Sm72PWm3T9mCtGsXLDU9zjQOAeja1FLCRoSKXak9WMInjozebdCvzEczNalWZqtS7N1aUCa5DKF_n7Vz82K2p_It7wE_NsBlI5cO_ImWEeDpdb5ZMK0o_ut_xOIaIXN</recordid><startdate>20110801</startdate><enddate>20110801</enddate><creator>Schmitt, Esther K</creator><creator>Moore, Charles M</creator><creator>Krastel, Philipp</creator><creator>Petersen, Frank</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110801</creationdate><title>Natural products as catalysts for innovation: a pharmaceutical industry perspective</title><author>Schmitt, Esther K ; Moore, Charles M ; Krastel, Philipp ; Petersen, Frank</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-69164231aa48dad34c0ba7c6e3381f5261a0995f84bea270b82031b65dae59463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Biodiversity</topic><topic>Biological Products - chemistry</topic><topic>Drug Discovery - methods</topic><topic>Drug Industry - methods</topic><topic>Epigenomics - methods</topic><topic>Genome</topic><topic>High-Throughput Screening Assays - methods</topic><topic>Humans</topic><topic>Molecular Probes - chemistry</topic><topic>Molecular Structure</topic><topic>Technology, Pharmaceutical - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmitt, Esther K</creatorcontrib><creatorcontrib>Moore, Charles M</creatorcontrib><creatorcontrib>Krastel, Philipp</creatorcontrib><creatorcontrib>Petersen, Frank</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in chemical biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmitt, Esther K</au><au>Moore, Charles M</au><au>Krastel, Philipp</au><au>Petersen, Frank</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Natural products as catalysts for innovation: a pharmaceutical industry perspective</atitle><jtitle>Current opinion in chemical biology</jtitle><addtitle>Curr Opin Chem Biol</addtitle><date>2011-08-01</date><risdate>2011</risdate><volume>15</volume><issue>4</issue><spage>497</spage><epage>504</epage><pages>497-504</pages><issn>1367-5931</issn><eissn>1879-0402</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><notes>ObjectType-Review-1</notes><abstract>Natural products are evolutionarily designed and chemically distinct from most synthetic library molecules. In addition to their role as drugs, they are successfully used as molecular probes to identify disease relevant targets. Novel natural products are still routinely discovered from traditional sources through cultivation of microorganisms. Complementary approaches based on genome sequence information and subsequent annotation of biosynthetic pathways are emerging technologies. However, to be of practical use for drug discovery, these concepts must be advanced beyond their current state.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>21684800</pmid><doi>10.1016/j.cbpa.2011.05.018</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1367-5931
ispartof Current opinion in chemical biology, 2011-08, Vol.15 (4), p.497-504
issn 1367-5931
1879-0402
language eng
recordid cdi_proquest_miscellaneous_892955080
source ScienceDirect Freedom Collection 2022-2024
subjects Biodiversity
Biological Products - chemistry
Drug Discovery - methods
Drug Industry - methods
Epigenomics - methods
Genome
High-Throughput Screening Assays - methods
Humans
Molecular Probes - chemistry
Molecular Structure
Technology, Pharmaceutical - methods
title Natural products as catalysts for innovation: a pharmaceutical industry perspective
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T06%3A35%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Natural%20products%20as%20catalysts%20for%20innovation:%20a%20pharmaceutical%20industry%20perspective&rft.jtitle=Current%20opinion%20in%20chemical%20biology&rft.au=Schmitt,%20Esther%20K&rft.date=2011-08-01&rft.volume=15&rft.issue=4&rft.spage=497&rft.epage=504&rft.pages=497-504&rft.issn=1367-5931&rft.eissn=1879-0402&rft_id=info:doi/10.1016/j.cbpa.2011.05.018&rft_dat=%3Cproquest_cross%3E892955080%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c421t-69164231aa48dad34c0ba7c6e3381f5261a0995f84bea270b82031b65dae59463%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=892955080&rft_id=info:pmid/21684800&rfr_iscdi=true